Multiple Endocrine Neoplasia Type 1
On this page:
Multiple endocrine neoplasia type 1 (MEN1) is an inherited disorder that affects the endocrine glands. It is sometimes called multiple endocrine adenomatosis or Wermer's syndrome, after one of the first doctors to recognize it. MEN1 is quite rare, occurring in about 3 to 20 persons out of 100,000. It affects both sexes equally and shows no geographical, racial, or ethnic preferences.
Endocrine glands are different from other organs in the body because they release hormones into the bloodstream. Hormones are powerful chemicals that travel through the blood, controlling and instructing the functions of various organs. Normally, the hormones released by endocrine glands are carefully balanced to meet the body's needs.
In patients with MEN1, sometimes multiple endocrine glands, such as the parathyroid, the pancreas, and the pituitary become overactive at the same time. Most people who develop overactivity of only one endocrine gland do not have MEN1.
[Top]
How does MEN1 affect the endocrine glands?
The Parathyroid Glands
The parathyroids are the endocrine glands earliest and most often affected by MEN1. The human body normally has four parathyroid glands, which are located close to the thyroid gland in the front of the neck. The parathyroids release into the bloodstream a chemical called parathyroid hormone, which helps maintain a normal supply of calcium in the blood, bones, and urine.
 In MEN1, all four parathyroid glands tend to be overactive. They release too much parathyroid hormone, leading to excess calcium in the blood. High blood calcium, known as hypercalcemia, can exist for many years before it is found by accident or by family screening. Unrecognized hypercalcemia can cause excess calcium to spill into the urine, leading to kidney stones or kidney damage.
Nearly everyone who inherits a susceptibility to MEN1 (a "cancer") will develop overactive parathyroid glands (hyperparathyroidism) by age 50, but the disorder can often be detected before age 20. Hyperparathyroidism may cause no problems for many years or it may cause problems such as tiredness, weakness, muscle or bone pain, constipation, indigestion, kidney stones, or thinning of bones.
Treatment of Hyperparathyroidism.
It is sometimes difficult to decide whether hyperparathyroidism in MEN1 is severe enough to need treatment, especially in a person who has no symptoms. The usual treatment is an operation to remove the three largest parathyroid glands and all but a small part of the fourth. After parathyroid surgery, regular testing of blood calcium should continue, since the small piece of remaining parathyroid tissue can grow larger and cause recurrent hyperparathyroidism. People whose parathyroid glands have been completely removed by surgery must take daily supplements of calcium and vitamin D to prevent hypocalcemia (low blood calcium).
The Pancreas Gland
The pancreas gland, located behind the stomach, releases digestive juices into the intestines and releases key hormones into the bloodstream. Some hormones produced in the islet cells of the pancreas and their effects are:
- insulin—lowers blood sugar;
- glucagon—raises blood sugar;
- somatostatin—inhibits many cells.
- Gastrin is another hormone that can be over secreted in MEN1. The gastrin comes from one or more tumors in the pancreas and small intestine. Gastrin normally circulates in the blood, causing the stomach to secrete enough acid needed for digestion. If exposed to too much gastrin, the stomach releases excess acid, leading to the formation of severe ulcers in the stomach and small intestine. Too much gastrin can also cause serious diarrhea.
About one in three patients with MEN1 has gastrin-releasing tumors, called gastrinomas. (The illness associated with these tumors is sometimes called Zollinger-Ellison syndrome.) The ulcers caused by gastrinomas are much more dangerous than typical stomach or intestinal ulcers; left untreated, they can cause rupture of the stomach or intestine and even death.
Treatment of Gastrinomas.
The gastrinomas associated with MEN1 are difficult to cure by surgery, because it is difficult to find the multiple small gastrinomas in the pancreas and small intestine. In the past, the standard treatment for gastrinomas was the surgical removal of the entire stomach to prevent acid production. The mainstay of treatment is now very powerful medicines that block stomach acid release, called acid pump inhibitors. Taken by mouth, these have proven effective in controlling the complications from high gastrin in most cases of Zollinger-Ellison syndrome.
The Pituitary Gland
The pituitary is a small gland inside the head, behind the bridge of the nose. Though small, it produces many important hormones that regulate basic body functions. The major pituitary hormones and their effects are:
- prolactin—controls formation of breast milk, influences fertility, and influences bone strength;
- growth hormone—regulates body growth, especially during adolescence;
- adrenocorticotropin (ACTH)—stimulates the adrenal glands to produce cortisol;
- thyrotropin (TSH)—stimulates the thyroid gland to produce thyroid hormones;
- luteinizing hormone (LH)—stimulates the ovaries or testes to produce sex hormones that determine many features of "maleness" or "femaleness"; and
- follicle stimulating hormone (FSH)—regulates fertility in men through sperm production and in women through ovulation.
The pituitary gland becomes overactive in about one of four persons with MEN1. This overactivity can usually be traced to a very small, benign tumor in the gland that releases too much prolactin, called a prolactinoma. High prolactin can cause excessive production of breast milk or it can interfere with fertility in women or with sex drive and fertility in men.
Treatment of Prolactinomas.
Some prolactinomas are small, and treatment may not be needed. If treatment is needed, a very effective type of medicine known as a dopamine agonist can lower the production of prolactin and shrink the prolactinoma. Occasionally, prolactinomas do not respond well to this medication. In such cases, surgery, radiation, or both may be needed.
[Top]
Rare complications of MEN1
Occasionally, a person who has MEN1 develops an islet tumor of the pancreas which secretes high levels of pancreatic hormones other than gastrin. Insulinomas, for example, produce too much insulin, causing serious low blood sugar, or hypoglycemia. Pancreatic tumors that secrete too much glucagon or somatostatin can cause diabetes, and too much vasoactive intestinal peptide can cause watery diarrhea.
Other rare complications arise from pituitary tumors that release high amounts of ACTH, which in turn stimulates the adrenal glands to produce excess cortisol. Pituitary tumors that produce growth hormone cause excessive bone growth or disfigurement.
Another rare complication is an endocrine tumor inside the chest or in the stomach, known as a carcinoid. In a person with MEN1 a carcinoid tumor rarely secretes a hormone. In general, surgery is the mainstay of treatment for all of these rare types of tumors, except for gastric carcinoids which usually require no treatment.
[Top]
Are the tumors associated with MEN1 cancerous?
The overactive endocrine glands associated with MEN1 may contain benign tumors, but usually they do not have any signs of cancer. Benign tumors can disrupt normal function by releasing hormones or by crowding nearby tissue. For example, a prolactinoma may become quite large in someone with MEN1. As it grows, the tumor can press against and damage the normal part of the pituitary gland or the nerves that carry vision from the eyes. Sometimes impaired vision is the first sign of a pituitary tumor in MEN1.
Another type of benign tumor often seen in people with MEN1 is a plum-sized, fatty tumor called a lipoma, which grows under the skin. Lipomas cause no health problems and can be removed by simple cosmetic surgery if desired. These tumors are also fairly common in the general population.
Benign tumors do not spread to or invade other parts of the body. Cancer cells, by contrast, break away from the primary tumor and spread, or metastasize, to other parts of the body through the bloodstream or lymphatic system.
The pancreatic islet cell tumors associated with MEN1 tend to be numerous and small, but most are benign and do not release active hormones into the blood.
Eventually, about half of MEN1 cases will develop a cancerous pancreatic tumor or a cancerous carcinoid tumor.
Treatment of Pancreatic Endocrine Cancer in MEN1.
Since the type of pancreatic endocrine cancer associated with MEN1 can be difficult to recognize, difficult to treat, and very slow to progress, doctors have different views about the value of surgery in managing these tumors.
One approach is to "watch and wait," using medical, or nonsurgical treatments. According to this school of thought, pancreatic surgery has serious complications, so it should not be attempted unless it will cure a tumor that is secreting too much hormone.
Another school advocates early surgery, perhaps when a tumor grows to a certain size, to prevent or remove pancreatic endocrine cancer in MEN1 (even if it does not over secrete a hormone) before it spreads and becomes dangerous. There is no clear evidence, however, that aggressive surgery to prevent pancreatic endocrine cancer from spreading actually leads to longer survival for patients with MEN1. This is partly because these complex operations can have their own side effects.
Doctors agree that excessive release of certain hormones (such as gastrin) from pancreatic endocrine cancer in MEN1 needs to be treated, and medications are often effective in blocking the effects of these hormones. Some tumors, such as insulin-producing tumors of the pancreas, are usually benign and single and are curable by pancreatic surgery. Such surgery needs to be considered carefully in each patient's case.
[Top]
Is MEN1 the same in everyone?
Although MEN1 tends to follow certain patterns, it can affect a person's health in many different ways. Not only do the features of MEN1 vary among members of the same family, but some families with MEN1 tend to have a higher rate of prolactin-secreting pituitary tumors and a much lower frequency of gastrin-secreting tumors.
In addition, the age at which MEN1 can begin to cause endocrine gland overfunction can differ strikingly from one family member to another. One person may have only mild hyperparathyroidism beginning at age 50, while a relative may develop complications from tumors of the parathyroid, pancreas, and pituitary by age 20.
Sometimes a patient with MEN1 knows of no other case of MEN1 among relatives. The commonest explanation is that knowledge about the family is incomplete; less often, the patient carries a new MEN1 gene mutation.
[Top]
Can MEN1 be cured?
There is no cure for MEN1 itself, but most of the health problems caused by MEN1 can be recognized at an early stage and controlled or treated before they become serious problems.
If you have been diagnosed with MENl, it is important to get periodic checkups because MEN1 can affect different glands, and even after treatment, residual tissue can grow back. Careful monitoring enables your doctor to adjust your treatment as needed and to check for any new disturbances caused by MEN1. Most MEN1 cases will have a long and productive life.
[Top]
How is MEN1 detected?
Each of us has millions of genes in each of our cells, which determine how our cells and bodies function. In people with MEN1, there is a mutation, or mistake, in one gene of every cell. A carrier is a person who has the MEN1 gene mutation. The MEN1 gene mutation is transmitted directly to a child from a parent carrying the gene mutation.
The MEN1 gene was recently identified. As of 2001, a small number of centers around the world began to offer MEN1 gene testing on a research or commercial basis. The likelihood of finding a mutation in an MEN1 family has varied from 60 percent to 95 percent depending on methods. When a mutation is found, further testing in other relatives can become much easier. Many relatives can be tested once and be found without the known MEN1 mutation in their family, and then they can be freed from uncertainty and from any further testing ever for MEN1. When a mutation is not found in a family or isolated case, it does not prove that no MEN1 mutation is present. Depending on the clinical and laboratory information, it may still be very likely that a mutation is present but undetected.
When the MEN1 mutation test is normal in an effected relative or when the test is not available, screening of close relatives of persons with MEN1, who are at high risk, generally involves testing for hyperparathyroidism, the most common and usually the earliest sign of MEN1.
[Top]
What is the role for genetic counseling with MEN1 gene testing?
Genetic counseling, which should accompany the gene testing, can assist family member(s) address how the test results affect them individually and as a family. In genetic counseling, there can be a review and discussion of issues about the psychosocial benefits and risks of the genetic testing results. Genetic testing results can affect self-image, self-esteem, and individual and family identity. In genetic counseling, issues related to how and with whom genetic test results will be shared and their possible effect on important matters such as health and life insurance coverage can be reviewed and discussed. The times for these discussions can be when a family member is deciding whether or not to go ahead with the gene testing and again later when the gene testing results are available. The person, who provides the genetic counseling to the family member(s), may be a professional from the disciplines of genetics, nursing, or medicine.
[Top]
Who should consider MEN1 screening by gene testing?
Screening may be offered to persons with MEN1 or with features resembling them. Affected relatives of persons with MEN1 can be tested. Asymptomatic offspring, brothers, or sisters of a person with MEN1 were born with a 50 percent chance of having inherited the gene; they too can be offered gene testing. While gene testing for any genetic disease can be definitive at any age, it is usually not offered to children below age 18 unless the test outcome would have an important effect on their medical treatment. Since treatable tumors occasionally begin by age 5 in MEN1, gene testing and tumor surveillance can begin at age 5.
[Top]
Who should consider MEN1 screening by laboratory tests?
MEN1 screening by gene testing will be the most definitive test, when it is available. However, it is not yet widely available, and, when no gene mutation is found in a MEN1 family, then it may be necessary to rely upon laboratory tests for diagnosis. Hyperparathyroidism, most often the first sign of MEN1, can usually be detected by blood tests between the ages of 5 and 50. Periodic tumor testing should begin between ages 5 to 10 and be repeated every year. There is no age at which periodic testing should stop, since (lacking a specific DNA test) doctors cannot rule out the chance that a person has inherited the MEN1 gene mutation. However, a person with normal tumor testing beyond age 50 is very unlikely to have inherited the MEN1 gene mutation.
[Top]
Why screen for MEN1 tumors?
MEN1 is not an infectious or contagious disease, nor is it caused by environmental factors. Because MEN1 is a genetic disorder inherited from one parent, and its transmission pattern is well understood, family members at 50–50 risk for the disorder can be easily identified.
Streamlined tumor testing can be used to identify an MEN1 carrier. After a carrier is identified, more detailed tumor surveys are generally recommended. Tumor testing can detect the problems caused by MEN1 tumors many years before their later complications develop. Finding these tumors early enables your doctor to begin preventive treatment, reducing the chances that MEN1 will cause problems later.
[Top]
Should a person who has MEN1 avoid having children?
A person who has MEN1 or who has a MEN1 gene mutation may have a hard time deciding whether to have a child. No one can make this decision for anyone else, but some of the important facts can be summarized as follows:
- A man or a woman with MEN1 has a 50–50 risk with each pregnancy of having a child with MEN1.
- MEN1 tends to fit a broad pattern within a given family, but the severity of the disorder varies widely from one family member to another. In particular, a parent's experience with MEN1 cannot be used to predict the eventual severity of MEN1 in a child.
- The tumor that result from MEN1 do not usually develop until adulthood. Treatment may require regular monitoring and considerable expense, but the disease usually does not prevent an active, productive adulthood.
- Prolactin-releasing tumors in a man or woman with MEN1 may inhibit fertility and make it difficult to conceive. Also, hyperparathyroidism in a woman during pregnancy may raise the risks of complications for mother and child.
Genetic counseling can help individuals and couples through the decision-making process with family planning. Genetic counselors and other professionals will provide information to help with the decision-making process, but they will not tell individuals or couples what decision to make or how to make it.
[Top]
Research in MEN1
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) was established by Congress in 1950 as part of the National Institutes of Health (NIH), whose mission is to improve human health through biomedical research. The NIH is the research arm of the Public Health Service under the U.S. Department of Health and Human Services.
The NIDDK conducts and supports a variety of research in endocrine disorders, including MEN1. NIDDK and other NIH researchers isolated the MEN1 gene in 1997. Researchers have also shown that the MEN1 gene contributes to common endocrine tumors outside of the setting.
[Top]
For More Information
The following articles about MEN1 can be found in medical libraries, some college and university libraries, and through interlibrary loan in most public libraries.
Chandrasekharappa, S.C., Guru, S.C., Manickam, P., Olufemi, S.,
Collins, F.S. Emmert-Buck, M.R., Debelenko, L.V., Zhuang, Z.,
Lubensky, I.A., Liotta, L.A., Crabtree, J.S., Wang, Y., Roe,
B.A., Weisemann, J., Boguski, M.S., Agarwal, S.K., Kester, M.B.,
Kim, Y.S., Heppner, C., Dong, Q., Spiegel, A.M., Burns, A.L.,
Marx, S.J., "Positional cloning of the gene for multiple
endocrine neoplasia-type 1," Science 276:404–407, 1997.
Marx SJ. Multiple endocrine neoplasia type 1. In: Metabolic Basis
of Inherited Diseases, 8th Ed. ed. Scriver CS, et al.
McGraw Hill, NY, 2001. pp 943–966.
Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ.
MEN1: New clinical and basic findings. Trends Endocrinol Metab 12: 173–178, 2001.
The following organizations might also be able to assist with certain types of information:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
Phone: 805–499–9973
Fax: 805–480–0633
Email: pna@pituitary.org
Internet: www.pituitary.org
Office of Communications and Public Liaison
National Institute of Diabetes and Digestive and Kidney Diseases
Building 31, Room 9A06
Bethesda, MD 20892
March of Dimes/Birth Defects Foundation
1275 Mamaroneck Avenue
White Plains, NY 10605
914–428–7100
Alliance of Genetic Support Groups
4301 Connecticut Avenue, NW., Suite 404
Washington, DC 20008–2304
Telephone: 202–966–5557
Helpline: 800–336–GENE (4363)
Fax: 202–966–8553
E-mail: info@geneticalliance.org
Home Page: www.geneticalliance.org
National Endocrine and Metabolic Diseases Information Service
6 Information Way
Bethesda, MD 20892–3569
Phone: 1–888–828–0904
TTY: 1–866–569–1162
Fax: 1–703–738–4929
Email: endoandmeta@info.niddk.nih.gov
Internet: http://endocrine.niddk.nih.gov/
The National Endocrine and Metabolic Diseases Information Service is an information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services.
The NIDDK conducts and supports biomedical research. As a public service the NIDDK has established information services to increase knowledge and understanding about health and disease among patients, health professionals and the public.
Publications produced by the NIDDK are carefully reviewed by both NIDDK scientists and outside experts.
This publication is not copyrighted. The NIDDK encourages users of this publication to duplicate and distribute as many copies as desired.
It was written by Stephen J. Marx, M.D. and reviewed by Robert T. Jensen, M.D., both of the National Institute of Diabetes and Digestive and Kidney Diseases.
NIH Publication No.06–3048
March 2006
[Top]
|
